LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MOLN
Molecular Partners AG
There isn't enough reported data to score MOLN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MOLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MOLN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | โ |
| Current | 46x | $1,427 | โ |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MOLN PE Valuation
MOLN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MOLN Forward outlook
There aren't enough analyst estimates for MOLN to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus MOLN down 187%.
MOLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$1.99 | -$0.08 |
| Q2 2025 | -$2.15 | -$0.04 |
| Q4 2024 | -$1.91 | +$0.37 |
| Q2 2024 | -$2.11 | +$0.15 |
| Q4 2023 | -$2.28 | -154% |
| Q4 2022 | $4.26 | +$6.74 |
| Q4 2021 | -$2.48 | +$0.65 |
| Q4 2020 | -$3.13 | -$1.08 |
MOLN is still losing money, but less than at its worst: $1.99 per share over the past year, against $3.13 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 100% for MOLN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
MOLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $819.8K | -81% |
| Q2 2024 | $5.2M | +24% |
| Q4 2023 | $4.3M | -29% |
| Q2 2023 | $4.2M | -98% |
| Q4 2022 | $6.1M | -48% |
| Q4 2021 | $11.7M | +531% |
| Q4 2020 | $1.9M | -55% |
| Q3 2020 | $340.7K | -92% |
MOLN's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -4315% | -3729 points |
| Q2 2024 | -742% | -822 points |
| Q4 2023 | -843% | -193 points |
| Q2 2023 | -894% | +405 points |
| Q4 2022 | -586% | +4775 points |
| Q2 2022 | 79% | +372 points |
| Q4 2021 | -650% | -329 points |
| Q4 2020 | -1299% | -944 points |
MOLN's operating margin was โ4315% last quarter, down 3729 points from the same quarter a year ago, near the bottom of its range since 2016.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with MOLN at down 283%.
MOLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$25.6M | +$6.8M |
| Q2 2025 | -$37M | +$2.8M |
| Q4 2024 | -$32.3M | +$3.3M |
| Q2 2024 | -$39.8M | -$3.7M |
| Q4 2023 | -$35.6M | +$4.3M |
| Q2 2023 | -$36.1M | -120% |
| Q4 2022 | -$39.9M | +$70.7M |
| Q4 2021 | -$110.6M | -4638% |
MOLN has burned cash in most quarters: โ$135M over the past year, against $70M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MOLN Net Leverage
MOLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MOLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.2 | Neutral |
| Stochastic | 4.6 | Oversold |
MOLN's weekly RSI is 30 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MOLN PE vs Healthcare Sector
| Metric | MOLN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
MOLN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MOLN on trend strength, trading above more of its moving averages.
MOLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.64 | 17% below |
| 20 week MA | $3.94 | 24% below |
| 50 week MA | $4.15 | 27% below |
| 100 week MA | $4.15 | 27% below |
| 200 week MA | $4.79 | 37% below |
MOLN is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MOLN on returns for 2026, with the stronger performance.
MOLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.3 | $20.2 | +4.9% |
| 2022 | $20.2 | $6.55 | -68% |
| 2023 | $6.55 | $4.18 | -36% |
| 2024 | $4.18 | $5.30 | +27% |
| 2025 | $5.30 | $4.23 | -20% |
| 2026 YTD | $4.23 | $3.01 | -29% |
MOLN has finished lower in three of the last five years. It's down 29% so far in 2026.